Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 29 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: dipyridamole Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-drug Interaction Study of Aggrenox and Omeprazole in Normal Volunteers

NCT01303445
View directory record Official record
Conditions
Healthy
Interventions
Aggrenox alone, Aggrenox and omeprazole, Omeprazole alone
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 23, 2013 · Synced Sep 2, 2026, 1:37 AM EDT
Completed Not applicable Interventional Results available

Clinical Trial of Dipyridamole in Schizophrenia

NCT00349973
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
Dipyridamole, Olanzapine
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 3, 2019 · Synced Sep 2, 2026, 1:37 AM EDT
Completed Not applicable Interventional Results available

GORE® Septal Occluder Device for Patent Foramen Ovale (PFO) Closure in Stroke Patients

NCT00738894
View directory record Official record
Conditions
Stroke, Transient Ischemic Attack
Interventions
Septal Occluder Device, Antiplatelet Medical Therapy
Device · Drug
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years to 60 Years
Enrollment
664 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Sep 2, 2026, 1:37 AM EDT
Recruiting Phase 2 Interventional

Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients

NCT06824454
View directory record Official record
Conditions
Hypophosphatemia, Kidney Transplantation
Interventions
Dipyridamole 75 MG
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 2, 2026, 1:37 AM EDT
Completed Phase 3 Interventional Results available

Aggrenox To Treat Acute Covid-19

NCT04410328
View directory record Official record
Conditions
Covid19
Interventions
Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care, Standard of care
Drug · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
19 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Sep 2, 2026, 1:37 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Trial Comparing Z-102 With Placebo In Patients With Moderate To Severe Rheumatoid Arthritis

NCT01369745
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Prednisolone, dipyridamole, Prednisone, Z102, placebo
Drug · Other
Lead sponsor
Zalicus
Industry
Eligibility
18 Years and older
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Sep 2, 2026, 1:37 AM EDT
Not listed Phase 4 Interventional

Lexiscan(TM) Rb-82 Myocardial Perfusion PET: A Comparison With Dipyridamole Stress

NCT00808314
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Rest/Dipyridamole Stress Rb-82 Myocardial Perfusion PET/CT, Rest/Lexiscan(TM) Stress Rb-82 Myocardial Perfusion PET
Drug
Lead sponsor
Cardiovascular Imaging Technologies
Industry
Eligibility
35 Years to 90 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Sep 2, 2026, 1:37 AM EDT
Completed Not applicable Interventional Results available

Coronary Flow Reserve to Assess Cardiovascular Inflammation (CIRT-CFR)

NCT02786134
View directory record Official record
Conditions
Coronary Heart Disease, Metabolic Syndrome, Diabetes Mellitus
Interventions
PET scan, Echocardiogram
Radiation
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Sep 2, 2026, 1:37 AM EDT
Withdrawn Phase 2 Interventional

Dipyridamole/Magnesium To Improve Sickle Cell Hydration

NCT00276146
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
oral dipyridamole, oral magnesium, or a combination of both
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years and older
Timeline
Started 2005
U.S. locations
3
States / cities
Detroit, Michigan • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 6, 2013 · Synced Sep 2, 2026, 1:37 AM EDT
Completed Phase 3 Interventional

Aggrenox Prevention of Access Stenosis

NCT00067119
View directory record Official record
Conditions
Kidney Failure
Interventions
Aggrenox, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
649 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
9
States / cities
Birmingham, Alabama • Iowa City, Iowa • Portland, Maine + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Sep 2, 2026, 1:37 AM EDT
Completed Phase 1 Interventional

Treatment of Supine Hypertension in Autonomic Failure

NCT00223717
View directory record Official record
Conditions
Hypertension
Interventions
Clonidine, Nitroglycerin transdermal, Dipyridamole/ Aspirin (Aggrenox), Desmopressin (DDAVP), Sildenafil, Nifedipine, Hydralazine, Hydrochlorothiazide, Placebo, Bosentan, Diltiazem, Eplerenone, guanfacine, L-arginine, captopril, carbidopa, losartan, metoprolol tartrate, nebivolol hydrochloride, prazosin hydrochloride, tamsulosin hydrochloride, Head-up tilt., aliskiren, Local heat stress
Drug · Dietary Supplement · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Sep 2, 2026, 1:37 AM EDT
Completed Not applicable Interventional Results available

Patent Foramen Ovale Closure or Medical Therapy After Stroke - RESPECT Trial

NCT00465270
View directory record Official record
Conditions
Cryptogenic Stroke
Interventions
AMPLATZER PFO Occluder, Standard of Care - Medical Management
Device · Other
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 60 Years
Enrollment
980 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
61
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 52 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2019 · Synced Sep 2, 2026, 1:37 AM EDT
Terminated Not applicable Interventional Results available

The Vascular Biology of Dipyridamole in Peripheral Arterial Disease (PAD)

NCT00906035
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Dipyridamole 200mg and Aspirin 25mg bid:, Dipyridamole 200 mg bid, Aspirin 25 mg bid
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 79 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
3
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 4, 2017 · Synced Sep 2, 2026, 1:37 AM EDT
Completed Not applicable Interventional Results available

Regadenoson Combined With Symptom-Limited Exercise in Patients Undergoing Myocardial Perfusion Imaging

NCT01021618
View directory record Official record
Conditions
Coronary Artery Disease, Myocardial Ischemia
Interventions
Regadenoson, Symptom-limited exercise
Drug · Other
Lead sponsor
Hartford Hospital
Other
Eligibility
30 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 20, 2013 · Synced Sep 2, 2026, 1:37 AM EDT
Terminated Phase 2 Interventional Results available

Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19

NCT04424901
View directory record Official record
Conditions
COVID-19 Pneumonia, Vascular Complications
Interventions
Placebo, Dipyridamole Tablets
Drug
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Sep 2, 2026, 1:37 AM EDT
Completed Phase 4 Interventional Results available

PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes

NCT00153062
View directory record Official record
Conditions
Stroke
Interventions
Aggrenox, Clopidogrel placebo, Micardis, Aggrenox placebo, Clopidogrel, Micardis placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
50 Years and older
Enrollment
20,332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
204
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 160 more
Source: ClinicalTrials.gov public record
Updated May 12, 2014 · Synced Sep 2, 2026, 1:37 AM EDT
Terminated Phase 4 Interventional Results available

Persantine: Variation in Response Trial

NCT00763009
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
dipyridamole
Drug
Lead sponsor
UConn Health
Other
Eligibility
21 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 12, 2018 · Synced Sep 2, 2026, 1:37 AM EDT
Terminated No phase listed Observational

Circulating Adenosine Levels Before and After Intravenous (IV) Persantine

NCT00760708
View directory record Official record
Conditions
Ischemia, Coronary Disease
Interventions
Not listed
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated May 13, 2019 · Synced Sep 2, 2026, 1:37 AM EDT
Terminated Not applicable Interventional Results available

Dipyridamole Assessment for Flare Reduction in Systemic Lupus Erythematosus (SLE)

NCT01781611
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
extended release dipyridamole 200mg/aspirin 25mg, 81mg aspirin
Drug
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Sep 2, 2026, 1:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Ticagrelor vs. Dipyridamole on Adenosine Uptake

NCT01690884
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Adenosine
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Sep 2, 2026, 1:37 AM EDT
Completed Phase 2 Interventional Results available

Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19

NCT04391179
View directory record Official record
Conditions
COVID, Corona Virus Infection, Covid-19, SARS-CoV-2 Infection
Interventions
Dipyridamole 100 Milligram(mg), Placebo oral tablet
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Sep 2, 2026, 1:37 AM EDT
Completed Phase 2 Interventional

S9700 Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer

NCT00003018
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
dipyridamole, fluorouracil, leucovorin calcium, mitomycin C
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
84
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2013 · Synced Sep 2, 2026, 1:37 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study of Blood Flow in Heart Muscle

NCT00001631
View directory record Official record
Conditions
Coronary Disease, Healthy, Hypertrophic Cardiomyopathy, Myocardial Ischemia
Interventions
Magnetic resonance imaging
Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 2, 2026, 1:37 AM EDT
Completed No phase listed Observational

Direct Comparison of 2D Cardiac PET With 3D Cardiac PET

NCT01993303
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Cardiovascular Imaging Technologies
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 24, 2013 · Synced Sep 2, 2026, 1:37 AM EDT